Skip to main content

Advertisement

SpringerLink
Log in

Refractory overactive bladder in men: Update on novel therapies

  • Published:
Current Urology Reports Aims and scope Submit manuscript

Abstract

Overactive bladder (OAB) in men is an entity that may be challenging to diagnose and treat, especially in the presence of bladder outlet obstruction. The application of oral medical treatments of lower urinary tract symptoms attributed to benign prostatic hyperplasia has traditionally utilized α-adrenergic blockers and 5α-reductase inhibitors. After failure of oral medical therapies, surgical options are traditionally offered. Even after surgical options are successful, lower urinary tract symptoms that are secondary to OAB persist. These patients merit a trial of antimuscarinic drugs. Additionally, certain patients with concomitant bladder outlet obstruction who have not been surgically relieved can still merit a trial of antimuscarinic drugs without significant risk of developing urinary retention. When these oral antimuscarinic drugs fail, options still remain for treating men with refractory OAB. Successful application of various diagnostic approaches and the initiation of conservative options as well as other options, such as neuromodulation for refractory urgency and urge incontinence, can help the patient. Finally, emerging data support the use of intradetrusor injections of botulinum toxin for refractory OAB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167.

    Article  PubMed  Google Scholar 

  2. Milsom I, Abrams P, Cardozo L, et al.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001, 87:760–766.

    Article  PubMed  CAS  Google Scholar 

  3. Kelleher C, Kreder K, Pleil A, et al.: Long-term healthrelated quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002, 8:S616-S630.

    PubMed  Google Scholar 

  4. Welch G, Weinger K, Barry MJ: Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002, 59:245–250.

    Article  PubMed  Google Scholar 

  5. de Groat WC: A neurologic basis for the overactive bladder. Urology 1997, 50:36–52.

    Article  PubMed  Google Scholar 

  6. Turner WH, Brading AF: Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment. Pharmacol Ther 1997, 75:77–110.

    Article  PubMed  CAS  Google Scholar 

  7. de Groat WC: The urothelium in overactive bladder: passive bystander or active participant? Urology 2004, 64(6 Suppl 1):7–11.

    PubMed  Google Scholar 

  8. Barry MJ, Cockett ATK, Holtgrewe HL, et al.: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993, 150:351–358.

    PubMed  CAS  Google Scholar 

  9. de a Rosette JJ, Witjes WP, Schaefer W, et al.: Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the ICS-“BPH” study. Neurourol Urodyn 1998, 17:99–108.

    Article  PubMed  Google Scholar 

  10. Lee JY, Kim HW, Lee SJ: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004, 94:817–820.

    Article  PubMed  CAS  Google Scholar 

  11. Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001, 166:550–552.

    Article  PubMed  CAS  Google Scholar 

  12. Herbison P, Hay-Smith J, Ellis G, et al.: Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2004, 326:841–844.

    Article  Google Scholar 

  13. Resnick NM, Yalla SV: Detrusor hyperactivity with impaired contractile function: an unrecognized but common cause of incontinence in elderly patients. JAMA 1987, 257:3076–3081.

    Article  PubMed  CAS  Google Scholar 

  14. Burgio KL, Locher JL, Goode PS: Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000, 48:370–374.

    PubMed  CAS  Google Scholar 

  15. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al.: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003, 169:2253–2256. This was the first randomized study to evaluate the efficacy of treatment with α-blockade and anticholinergic therapy in men with BOO and LUTS. Contrary to previous concerns regarding the risk of urinary retention in patients’ anticholinergic treated BPH, there were no episodes of urinary retention in the placebo or tolterodine groups. The tolterodine group had better overall symptom improvement in addition to the moderate urodynamic benefits.

    Article  PubMed  CAS  Google Scholar 

  16. Schwinn DA, Price DT, Perinchery N: Alpha-1 adrenoreceptor subtype selectivity and lower urinary tract symptoms. Mayo Clin Proc 2004, 79:1423–1434. This is an extensive review on the title topic.

    Article  PubMed  CAS  Google Scholar 

  17. Van Venrooij GE, Van Melick HH, Eckhardt MD, et al.: Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol 2002, 168:605–609.

    Article  PubMed  Google Scholar 

  18. Leng WW, Davies BJ, Tarin T, et al.: Delayed treatment of bladder outlet obstruction after sling surgery: association with irreversible bladder dysfunction. J Urol 2004, 172:1379–1381.

    Article  PubMed  Google Scholar 

  19. Wein AJ, Rackley RR: Overactive bladder: a better understanding of pathophysiology, diagnosis, and management. J Urol 2006, 175:S5-S10.

    Article  PubMed  Google Scholar 

  20. Abrams P, Kaplan S, De Koning Gans HJ, Millard R: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006, 175:999–1004.

    Article  PubMed  CAS  Google Scholar 

  21. Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al.: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003, 169:2253–2256.

    Article  PubMed  CAS  Google Scholar 

  22. Kaplan SA, Walmsley K, Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005, 174:2273–2275.

    Article  PubMed  Google Scholar 

  23. Anderson RU, Mobley D, Blank B, et al.: Once-daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. J Urol 1999, 161:1809–1812.

    Article  PubMed  CAS  Google Scholar 

  24. Larsson G, Hallen B, Nilvebrant L: Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 1999, 53:990–998.

    Article  PubMed  CAS  Google Scholar 

  25. Chapple C, Steers W, Norton P, et al.: A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005, 85:993–1001.

    Article  CAS  Google Scholar 

  26. Tanagho EA, Schmidt RA, Orvis BR: Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders. J Urol 1989, 142:340–345.

    PubMed  CAS  Google Scholar 

  27. Jonas U, Fowler CJ, Chancellor MB, et al.: Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol 2001, 165:15–19.

    Article  PubMed  CAS  Google Scholar 

  28. Groen J, Ruud Bosch J, van Mastrigt R: Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding. J Urol 2006, 175:1005–1009.

    Article  PubMed  Google Scholar 

  29. Latini JM, Alipour M, Kreder KJ: Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence. Urology 2006, 67:550–553.

    Article  PubMed  Google Scholar 

  30. Annese V, Basciani M, Borrelli O, et al.: Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia. Muscle Nerve 1998, 21:1540–1542.

    Article  PubMed  CAS  Google Scholar 

  31. Yoshida M, Inadome A, Maeda Y: Non-neuronal cholinergic system in human bladder urothelium. Urology 2006, 67:425–430.

    Article  PubMed  Google Scholar 

  32. Apostolidis A, Dasgupta P, Fowler CJ: Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Euro Urol 2006, 49:644–650.

    Article  CAS  Google Scholar 

  33. Schurch B, Stohrer M, Kramer G, et al.: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000, 164:692–697.

    Article  PubMed  CAS  Google Scholar 

  34. Schurch B, de Seze M, Denys P, et al.: Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005, 174:196–200. This is the first randomized study in patients with urinary incontinence caused by DO. It demonstrates the efficacy and tolerability of BTX. This study provides important data in support of the use of BTX-A injection in DO patients.

    Article  PubMed  CAS  Google Scholar 

  35. Schmid DM, Sauermann P, Werner M, et al.: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006, 176:177–185.

    Article  PubMed  CAS  Google Scholar 

  36. Hoebeke P, De Caestecker K, Vande Walle J, et al.: The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 2006, 176:328–330.

    Article  PubMed  CAS  Google Scholar 

  37. Smith CP, Chancellor MB: Simplified bladder botulinum toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol 2005, 19:880–882.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Weill Medical College of Cornell University, 525 E. 68th St., F-9 West, Box 261, 10021, New York, NY, USA

    Alexis E. Te MD

Authors
  1. Casey K. Ng MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ricardo R. Gonzalez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alexis E. Te MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ng, C.K., Gonzalez, R.R. & Te, A.E. Refractory overactive bladder in men: Update on novel therapies. Curr Urol Rep 7, 456–461 (2006). https://doi.org/10.1007/s11934-006-0054-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11934-006-0054-5

Keywords

Search

Navigation